Semaglutide

Test Reports

10 MG - SM1212JF - 02/05/2025

5 MG - SM5103JF - 1/21/2025

10 MG - SG10FTJ - 11/25/2024

5 MG - SGM5FTJ - 11/25/2024

5 MG - 8U8CIA - 10/10/2024

10 MG - EL1FTJ - 09/25/2024

10 MG - CH3MY8 - 09/17/2024

5 MG - 4ZC0G5- 09/17/2024

10 MG - 7HF3CUU- 08/09/2024

5 MG - C3LIAJ7J9C - 05/07/2024

Properties

Semaglutide Peptide Synopsis

Derived from the naturally occurring peptide GLP-1, Semaglutide has been shown to lower blood sugar levels and increase insulin production. It has also been proven to improve heart, liver, and lung function while potentially slowing or halting the progression of Alzheimer's disease. Studies have demonstrated that Semaglutide reduces appetite by delaying gastric emptying and decreasing intestinal motility. GLP-1 analogues have also been found to regulate insulin and glucagon release in a glucose-dependent manner.

Semaglutide Peptide & GLP-1 Research

GLP-1 Research

GLP-1, or glucagon-like peptide-1, is a naturally occurring peptide hormone that is 30-31 amino acids long. Its primary function is to lower blood sugar levels by increasing insulin secretion. In addition, it is involved in protecting insulin stores and promoting insulin gene transcription in beta cells. Studies have also linked GLP-1 with neurotrophic effects in the central nervous system. In the digestive system, GLP-1 can decrease appetite by slowing down gastric emptying and reducing intestinal motility. Research has also shown that GLP-1 has potential impacts on the heart, fat, muscles, bones, liver, lungs, and kidneys.

The main area of GLP-1 research has traditionally been in treating and preventing diabetes, as well as suppressing appetite. Secondary studies have explored the peptide's potential cardiovascular advantages. More recent, although less definitive, research delves into GLP-1's ability to delay or prevent neurodegenerative diseases. Although newer, this field of research is rapidly expanding as the peptide has been found to slow or prevent the buildup of amyloid beta plaques in individuals with Alzheimer's disease.

Beta Cells Research

Studies in animal models have revealed that GLP-1 has the potential to stimulate growth and multiplication of pancreatic beta cells. Additionally, it has been shown to prevent beta cell death and promote differentiation of new beta cells from pancreatic duct epithelium. Overall, these findings indicate that GLP-1 could potentially be beneficial in treating diabetes and safeguarding the pancreas against harm that could harm beta cells.

In an exceptionally impactful study, GLP-1 was proven to prevent the degradation of beta cells triggered by heightened levels of inflammatory substances. In fact, experiments on mice with type 1 diabetes have indicated that GLP-1 safeguards islet cells from destruction and could potentially serve as a means of preventing the development of type 1 diabetes.

Incretin Research

GLP-1's potentially most significant impact is through the stimulation of the incretin effect within the GI tract, causing a reduction in blood glucose levels. In rodent models, GLP-1 and GIP are identified as the two primary hormones responsible for this effect, with GLP-1 being more potent than GIP, especially in cases of high blood glucose levels.

A GLP-1 receptor has been uncovered on the surface of pancreatic beta cells, indicating that GLP-1 directly stimulates insulin release from the pancreas. When used with sulfonylurea medications, GLP-1 has been proven to enhance insulin secretion, resulting in mild hypoglycemia in nearly 40% of patients. This rise in insulin production is linked with various beneficial impacts, such as heightened protein synthesis, reduced protein breakdown, and increased absorption of amino acids by skeletal muscle.

Appetite Research

Studies on mice have indicated that by administering GLP-1, as well as its related counterpart GLP-1, into their brains, there is a decrease in the desire to eat and a reduction in food intake. In fact, GLP-1 may enhance feelings of fullness, ultimately leading to a decrease in hunger. Recent clinical research has revealed that when mice were given GLP-1 receptor agonists twice a day, they experienced gradual and consistent weight loss. This sustained weight loss has been connected to a notable improvement in cardiovascular risk factors and a decrease in hemoglobin A1C levels - a key indicator of the severity of diabetes and the effectiveness of treatment in controlling blood sugar levels.

Cardiovascular Research

The GLP-1 receptors are found throughout the heart and have been shown to enhance cardiac function in specific circumstances by increasing heart rate and decreasing left ventricular end-diastolic pressure. While this may seem insignificant, elevated LV end-diastolic pressure has been linked to LV hypertrophy, cardiac changes, and eventual heart failure.

New research has indicated that GLP-1 may have a role in reducing the overall damage caused by a heart attack. It seems that this peptide enhances glucose absorption in cardiac muscles, providing essential nourishment for ischemic cells and preventing programmed cell death. The increase in glucose uptake in these cells appears to be independent of insulin.

Infusing large amounts of GLP-1 into canines has proven to enhance LV function and diminish systemic vascular resistance. This can aid in lowering blood pressure and alleviating stress on the heart. As a result, it can mitigate potential repercussions of prolonged high blood pressure, such as LV remodeling, thickening of blood vessels, and heart failure.

Neurological Research

Some evidence suggests that GLP-1 can enhance memory and act as a safeguard for neurons against neurodegenerative ailments, like Alzheimer's disease. A study showed that GLP-1 can augment associative and spatial learning in mice and even improve deficits in mice with gene abnormalities. In rats with GLP-1 receptor over-expression in certain brain regions, memory and learning are notably superior compared to their normal counterparts.

Further studies in mice have demonstrated the potential of GLP-1 to safeguard against excitotoxic neuron damage and fully defend rats with neurodegenerative disorders from glutamate-induced apoptosis. The peptide also has the ability to promote neurite outgrowth in cultured cells, giving researchers hope for possible uses in preventing or reversing certain types of neurodegenerative diseases.

GLP-1 and its analogue exendin-4 have been observed to decrease amyloid-beta levels in the brain and beta-amyloid precursor protein in neurons in mouse models. This protein is the main component of the plaques seen in Alzheimer's, which, while not definitively linked to the disease, are associated with its severity. It is uncertain if stopping amyloid-beta buildup can prevent Alzheimer's, but this study offers an enticing hint at how researchers may intervene in the progression from mild cognitive impairment to full disease.

GLP-1 demonstrates minimal to moderate adverse effects, with low oral and excellent subcutaneous absorption in mice. Dosages per kg in mice may not translate to humans. Peptide Sciences offers GLP-1 for purchase only for educational and scientific research purposes, not for consumption by humans. Purchase GLP-1 only if you are a licensed researcher.

All product descriptions and details found on this website are intended for educational, research and informational purposes only.